Ototoxicity in Hemoglobinopathy Patients Chelated with Desferrioxamine
Authors:
- Elliott P. VichinskyEVElliott P. Vichinsky
- 1 February 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 18 (1) , 42-45
Abstract
Purpose Ototoxicity often limits the dose of desferrioxamine (DFO) tolerated by patients who are transfusion dependent. Current recommendations advise doses of <50 mg/kg/day after early reports noted higher rates of ototoxicity with increasing doses. There have been no follow-up studies to determine the effect of this recommendation on ototoxicity and iron overload. Methods We followed 28 patients who were chronically chelated with serial audiograms over a 5-year period. Patients with and without ototoxicity were compared with respect to age, disease, DFO dose, peak DFO dose, length of DFO therapy, ferritin, and therapeutic index. Results Eight of the 28 patients (29%) had an abnormal audiogram during threshold testing. Two patients had two separate episodes with hearing deficit. Nine of the 10 episodes were highfrequency losses, with seven being moderate and three mild. All deficits were rapidly reversible with DFO dose reduction. No significant differences were found between the affected and unaffected groups with respect to age, DFO dose or duration, feritin, or therapeutic index. Numbers of afected patients were small, but patients with SCD differed from patients with thalassemia in that they developed ototoxicity earlier and with lower doses of DFO and lower therapeutic indexes. Conclusions Despite DFO doses usually felt to be low risk for ototoxicity, we found a high rate of ototoxicity in our patients who we've chronically chelated. No variables were identified that reliably predicted ototoxicity. We stress the need for regular audiological exams and feel no dose of DFO is “safe” from the development of ototoxicity.Keywords
This publication has 11 references indexed in Scilit:
- Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia MajorNew England Journal of Medicine, 1995
- Iron-balance and dose-response studies of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell diseaseBlood, 1994
- Hearing impairment during deferoxamine therapy for thalassemia majorThe Journal of Pediatrics, 1991
- Vision and hearing during deferoxamine therapyThe Journal of Pediatrics, 1990
- Treatment of Cooley's anemia [see comments]Blood, 1990
- Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosageBritish Journal of Haematology, 1989
- 11 The toxic effects of desferrioxamineBailliere's Clinical Haematology, 1989
- Hearing Loss and Desferrioxamine in Homozygous Beta-ThalassemiaInternational Journal of Audiology, 1988
- Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapyThe American Journal of Medicine, 1987
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986